Merck (MRK) announced its Q4 2018 financial results. The firm outperformed itself and delighted us with regard to picking its stock on time. Merck compensated those who bet on it the day it was added to the Prohost Portfolio that comprises only the biotech and bio-pharmaceutical companies with solid scientific fundamentals.

The press release issued regarding Merck's financial results started with Kenneth C. Frazier, Chairman and Chief Executive Officer of Merck sating, “Last year was a strong one for Merck marked by substantial progress on scientific and commercial fronts. The fourth . . .